PRIMARY OBJECTIVE: The purpose of the current study is to assess the role of the APOE genotype in post-traumatic seizure (PTS) development. RESEARCH DESIGN: A retrospective study of 322 adult Caucasians with a severe TBI and APOE genotype. METHODS AND PROCEDURES: Medical records were searched for PTS. Time to first seizure was categorized as early, late or delayed-onset PTS. Potential PTS associations by genotype, grouped genotype and allele were investigated. MAIN OUTCOME AND RESULTS: No statistically significant associations were found. However, two out of the four individuals (50%) with the E4/E4 genotype had late/delayed-onset PTS. Furthermore, none with a E2/E2 or E2/E4 genotype seized in the late periods. CONCLUSIONS: The results of this study may suggest 4/4 as a risk genotype for late/delayed onset PTS and a potential neuroprotective role of the E2 allele. However, this study did not definitively support a role for the APOE genotype in PTS susceptibility and indicates that larger populations are needed to fully evaluate the potential impact of APOE on PTS.
PRIMARY OBJECTIVE: The purpose of the current study is to assess the role of the APOE genotype in post-traumatic seizure (PTS) development. RESEARCH DESIGN: A retrospective study of 322 adult Caucasians with a severe TBI and APOE genotype. METHODS AND PROCEDURES: Medical records were searched for PTS. Time to first seizure was categorized as early, late or delayed-onset PTS. Potential PTS associations by genotype, grouped genotype and allele were investigated. MAIN OUTCOME AND RESULTS: No statistically significant associations were found. However, two out of the four individuals (50%) with the E4/E4 genotype had late/delayed-onset PTS. Furthermore, none with a E2/E2 or E2/E4 genotype seized in the late periods. CONCLUSIONS: The results of this study may suggest 4/4 as a risk genotype for late/delayed onset PTS and a potential neuroprotective role of the E2 allele. However, this study did not definitively support a role for the APOE genotype in PTS susceptibility and indicates that larger populations are needed to fully evaluate the potential impact of APOE on PTS.
Authors: Christian LoBue; Hannah Wadsworth; Kristin Wilmoth; Matthew Clem; John Hart; Kyle B Womack; Nyaz Didehbani; Laura H Lacritz; Heidi C Rossetti; C Munro Cullum Journal: Clin Neuropsychol Date: 2016-11-18 Impact factor: 3.535
Authors: Asla Pitkänen; Katarzyna Lukasiuk; F Edward Dudek; Kevin J Staley Journal: Cold Spring Harb Perspect Med Date: 2015-09-18 Impact factor: 6.915
Authors: Shaun D Darrah; Megan A Miller; Dianxu Ren; Nichole Z Hoh; Joelle M Scanlon; Yvette P Conley; Amy K Wagner Journal: Epilepsy Res Date: 2012-07-26 Impact factor: 3.045
Authors: Solomon M Adams; Yvette P Conley; Amy K Wagner; Ruchira M Jha; Robert Sb Clark; Samuel M Poloyac; Patrick M Kochanek; Philip E Empey Journal: Pharmacogenomics Date: 2017-10-04 Impact factor: 2.533
Authors: Charles A McFadyen; Frederick A Zeiler; Virginia Newcombe; Anneliese Synnot; Ewout Steyerberg; Russel L Gruen; Jonathan Rosand; Aarno Palotie; Andrew I R Maas; David K Menon Journal: J Neurotrauma Date: 2019-09-17 Impact factor: 5.269